Edwards Lifesciences Corp.

Edwards Lifesciences Corp. has achieved a new 52-week high, reflecting its strong market position in the Pharmaceuticals & Biotechnology sector. With a market capitalization of approximately USD 49,952 million, the company demonstrates effective management through a notable return on equity, despite a lack of dividend yield.

Edwards Lifesciences Corp. has achieved a new 52-week high, reflecting its strong position in the Pharmaceuticals & Biotechnology sector. The company has shown modest performance over the past year, with a solid return on equity and a low debt-to-equity ratio, despite a slight decline in profits.

Edwards Lifesciences Corp. has achieved a new 52-week high, reflecting its strong position in the Pharmaceuticals & Biotechnology sector. The company, with a market capitalization of approximately USD 49,952 million, has shown a modest performance increase over the past year and maintains a solid balance sheet with efficient management.

Edwards Lifesciences Corp. has demonstrated notable stock activity, achieving an intraday high and outperforming the S&P 500 over the past week. The company reports a strong return on equity and a low debt-to-equity ratio, reflecting solid financial health amid fluctuations in cash flow and profitability.

Edwards Lifesciences Corp. has recently adjusted its valuation, with its stock price at $79.71. Over the past year, the company has achieved a 15.19% stock return, contrasting with the S&P 500's 36.95%. Key financial metrics include a P/E ratio of 34 and an EV to EBITDA ratio of 27.38.

Edwards Lifesciences Corp. has recently adjusted its valuation, with its stock price at $77.87, down from $79.15. Over the past year, the company has seen a 14.08% stock return, lagging behind the S&P 500. Key financial metrics include a P/E ratio of 34 and an EV to EBITDA ratio of 27.38.

Edwards Lifesciences Corp. faced a challenging market on April 9, 2026, with a significant decline in stock value. Year-to-date, the company has seen a drop, contrasting with the S&P 500's performance. Despite a strong return on equity, profits have decreased, indicating potential concerns regarding its financial health.

Edwards Lifesciences Corp. faced a significant stock decline, reaching an intraday low of USD 78.58. Over the past week and month, the stock has decreased, though it has shown a positive return over the past year. The company maintains strong management efficiency and a fair valuation relative to peers.

Edwards Lifesciences Corp. faced a decline on March 13, 2026, reaching an intraday low of USD 81.34. Despite mixed performance metrics, the company holds a market capitalization of USD 47.65 billion and a return on equity of 22.80%, reflecting effective management efficiency.

Edwards Lifesciences Corp., a leader in medical technologies, has recently seen a revision in its market evaluation. The company’s stock has shown a strong annual return, outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting the company's adaptability in the competitive biotechnology sector.

Edwards Lifesciences Corp. has experienced significant activity, outperforming the S&P 500 in both short-term and long-term metrics. The company maintains a strong return on equity and a low debt-to-equity ratio, indicating solid financial health as it competes in the pharmaceuticals and biotechnology sectors.

Edwards Lifesciences Corp. demonstrated strong market performance, achieving an intraday high and outperforming the S&P 500 over the past week and year. With a market capitalization of approximately USD 47.65 billion, the company exhibits high management efficiency and a solid financial position, reflected in its return on equity and low debt-to-equity ratio.

Edwards Lifesciences Corp. saw a significant stock price increase on February 24, 2026, outperforming the S&P 500. Over the past week, the stock rose notably, although it experienced a slight decline over the month. The company maintains strong financial metrics, including a high return on equity and low debt-to-equity ratio.

Edwards Lifesciences Corp. opened with a notable gain, outperforming the S&P 500. Despite a recent monthly decline, the company showcases strong financial metrics, including a high return on equity and low debt-to-equity ratio. Technical indicators suggest a mildly bullish trend, with a positive annual return despite slight profit decreases.

Edwards Lifesciences Corp. has demonstrated notable stock activity, reaching an intraday high and outperforming the S&P 500 over the past week. Despite recent fluctuations, the company maintains a strong market position in the Pharmaceuticals and Biotechnology sector, supported by high management efficiency and a stable financial structure.

Edwards Lifesciences Corp. achieved a new 52-week high of USD 87.09 on October 31, 2025, despite a one-year performance decline. With a market cap of USD 48,455 million, the company shows strong financial metrics, including a P/E ratio of 30.00 and a return on equity of 14.74%.

Edwards Lifesciences Corp. achieved a new 52-week high of USD 84.66 on October 29, 2025, despite a one-year performance decline of 3.96%. With a market cap of USD 48,455 million, the company has a P/E ratio of 30.00 and a return on equity of 14.74%.

Edwards Lifesciences Corp. has recently revised its evaluation amid changing market conditions. The stock is currently priced at $80.82, reflecting a notable increase. Technical indicators show mixed performance, with varying trends across different timeframes. The company's returns have lagged behind the S&P 500 over longer periods.